Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 44.00p 43.00p 45.00p 44.00p 44.00p 44.00p 87,078 07:56:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.5 -7.4 -8.7 - 32.92

Angle Share Discussion Threads

Showing 46426 to 46450 of 46450 messages
Chat Pages: 1858  1857  1856  1855  1854  1853  1852  1851  1850  1849  1848  1847  Older
DateSubjectAuthorDiscuss
19/8/2017
14:15
https://www.ft.com/content/5e49e822-828c-11e7-a4ce-15b2513cb3ff
rwatson2
19/8/2017
08:44
Think some were buys being offered under the share price outsize.
maxie23
18/8/2017
23:49
Something unusual today - almost all sells, and the MMs didn't shift the price down.
outsizeclothes.com
18/8/2017
16:08
Thanks SV got it. Good write up.
maxie23
18/8/2017
15:57
O/t. Bermuda got in just under 11p, so yes. (Not a fan of management there though. Too many false dawns, but one day someone might come knocking!). Don't post there as full of nutters
waterloo01
18/8/2017
15:52
Just google Angle plc Financial Times - came up ok for me.
semper vigilans
18/8/2017
15:51
Thanks Waterloo.
maxie23
18/8/2017
15:49
Waterloo - hope you've got in at the bottom lol! Yes good for both and just good to see small bios get some coverage.
bermudashorts
18/8/2017
15:47
need to register with FT. get 5 articles free per month unless subscribe
waterloo01
18/8/2017
15:46
Thanks Bermuda but when l tried link it seems that you have to subscribe.
maxie23
18/8/2017
15:42
Cheers. Not sure they have the market cap quite right! Nice for SCLP as well (been in and out years ago but recently taken small stake again)
waterloo01
18/8/2017
15:35
Nice little piece on Angle in the FT hXXps://www.ft.com/content/5e49e822-828c-11e7-a4ce-15b2513cb3ff
bermudashorts
18/8/2017
14:01
The finishing line, as in FDA approval for Parsortix for breast cancer. It would be a major inflection point and would be reflected in any valuation of the Parsortix system by potential partners.
bermudashorts
18/8/2017
13:02
Bermuda.what make you think rhat we are just before finishing line ?
myszka21
18/8/2017
08:21
Life Guard, Sorry should make myself clear, I'm not saying that AGL have sufficient funds to carry out breast cancer trial. At Y/E they had £5.5m in the bank and a tax credit of £1.3m due on top of that. I understand that 3rd party expenses for the breast cancer trial will run at around £1.6m in this financial year but of course that's in addition to usual running costs and there is also still some work being carried out on the ovarian cancer study. I'm not sure I agree with your last sentence. The Company may decide to go down the partnering route but I wouldn't rule out a standard equity funding. The whole field of liquid biopsies is really hotting up and funds will be used for a pivotal trial leading (subject to results) to marketing approval from the FDA. There should be significant interest and Angle should be able to get a placing away on quite decent terms. My own preference would be to go down this route to maximise value rather than cutting a deal just before the finishing line.
bermudashorts
18/8/2017
07:24
Thanks Boom Is the tax credit added to balance sheet ? If so will this be sufficient to complete breast trial I do not think so ..pleased to be over ruled on this.. AN is now imo being forced into giving up total control and find a financial partner If Parsortix is as good as we believe it to be then he should find one
life guard
17/8/2017
18:04
Life Guard - there is also a £1.3m R&D tax credit due. With ovarian cancer trial costs dropping off but breast cancer trials due to start I would guess the burn rate would be broadly similar to last financial year.
bermudashorts
17/8/2017
17:27
Okay this is my guess at where we are for financials By all means add your own estimates 5.9 million to end of April We know FD Ian gets twitchy when funds start to get low So 3 million is his base line If cash burn is 500k per month Income 100k per month At end August we have 4.3 million in bank We are planning Breast trial Prostate trial And further Ovarian trial We have 1.3 million left We cannot commence a thing without funding to complete trial Hence my point on funding needs or we tread water for next couple of months As I said please do correct me with any thoughts welcome I might be missing something
life guard
17/8/2017
11:51
M21 probably yes as he owns what is it 9m shares or something. Get your point on the salary. Let's see what this year brings. I concede it does appear excessive v sales.
darrenpilbeam
17/8/2017
11:46
M21 probably yes as he owns what is it 9m shares or something. Get your point on the salary. Let's see what this year brings. I concede it does appear excessive v sales.
darrenpilbeam
17/8/2017
11:26
Article in today's Times. Up to three quarters of cases of some of the deadliest cancers can be detected in their early stages with a blood test that identifies tiny fragments of DNA shed by the tumours. It raises the prospect that people who appear healthy can be screened at regular NHS check-ups, giving doctors the chance to treat their diseases long before serious symptoms appear. The majority of cancers are only discovered once they have begun to spread around the body, making the tumours far harder to eliminate. The problem is particularly acute in slower-growing cancers, such as those of the lung, pancreas, bowel and ovaries, which together kill 65,000 people a year in the UK. Scientists are working on “pan-cancer221; blood tests that can give patients and their doctors an early warning while survival chances are still good. Until now most of these DNA technologies have only been tried on people with advanced cancer. Researchers at Johns Hopkins University, Baltimore, have shown for the first time that the “liquid biopsy” approach can accurately identify four of the most common cancers — breast, bowel, lung and ovarian — while they are still small and local enough to be vulnerable. Their findings, published in the journal Science Translational Medicine, are an important step towards being able to remove many cancers before they do any obvious damage to the body. At present the test costs about £1,500 but should get cheaper as the cost of sequencing people’s genomes falls. “These are all very common cancer types. All of them suffer from the fact that if you detect the cancer too late then patients do very poorly,” said Victor Velculescu, professor of oncology at Johns Hopkins and one of the study’s authors. “The thought is that if you can detect these early, you can surgically resect them or treat them with other therapies while they are still going to be effective.” The researchers drew up a set of 58 genes known to be markers of cancer and repeatedly sequenced DNA in the blood of 200 recently diagnosed patients.
sheath
17/8/2017
11:09
Darren.do you really think that An cares about dillution when awarded himself a filthy bonus worth pretty much the same as sales for whole year ????
myszka21
17/8/2017
10:47
Bloody well hope so and that it's got further than just looking at it!
semper vigilans
17/8/2017
10:45
On this funding issue that seems to keep cropping up all the time what has changed from the fact that the company had £5.3m at fin year end? Given the nature of Angle's business, it will also likely be receiving R&D grants/credits periodically which would help out (its not peanuts by the way). I would also imagine that as the company is generating income/revenues they will also have access to other non equity diluting finance too.
darrenpilbeam
17/8/2017
10:39
Perhaps he is looking at other options that will not involve dilution of shares.
maxie23
Chat Pages: 1858  1857  1856  1855  1854  1853  1852  1851  1850  1849  1848  1847  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20170820 00:33:09